. Grossesse-au-cours, ?. Oui, ?. Non, ?. Sans, and S. Oui, issue de la grossesse : Bibliographie (1) La bêta-thalassémie : Encyclopédie Orphanet Grand Public. www.orpha.net/data, upload.wikimedia.org/wikipedia

D. Labie and J. Elion, Bases mol??culaires et physiopathologiques des maladies de l'h??moglobine, EMC - H??matologie, vol.2, issue.4, pp.220-239, 2005.
DOI : 10.1016/j.emch.2005.10.001

. Phenotype-genotype, Relationships in monogenic disease: lessons from the thalassaemias D, J.Weatherall, vol.2, pp.245-255, 2001.

A. Rafai and I. Slassi, La presse médicale novembre 2014

F. Maazouna, J. Gellen-dautremera, A. Boutekadjirtc, S. Pissard, A. Habibi et al., Hématopoïèse extra-médullaire symptomatique au cours des bêtathalassémies : étude rétrospective monocentrique, Revue de Medecine Interne, vol.4986, issue.1011, 2015.

D. Pathophysiology, S. Cold, . Harb, and . Med, (12) Surcharges en fer et maladies Hématologiques. Christian Rose. La revue du praticien 15 décembre, pp.11726-2141, 2006.

. Wood, The heart in transfusion dependent homozygous thalassaemia today ? prediction, prevention and management. Aessopos a, Berdoukas v, Tsironi m Molecular Aspects of Bone Resorption in ?-Thalassemia Major, Blood Rev. European Journal of Haematology. Feb Cell journal, vol.22, issue.17 2, pp.14-21, 2008.

. Moutou, . Rev, . Méd, . Périnat, L. Janet et al., A genetic score for the prediction of beta-thalassemia severity (29) HAS. Transfusion de globules rouges homologues : produits, indications alternatives Méthode Recommandations pour la pratique clinique http://www.has-sante.fr/portail/upload/docs/application/pdf/2015- 02/transfusion_de_globules_rouges_homologues_- _produits_indications_alternatives_-_recommandations.pdf (30) Real-World Use of Iron Chelators Update on Iron Chelators in Thalassemia, ) Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Ellis J. Neufeld. Blood, pp.53-60, 2010.

A. , J. Baksi, and D. J. Pennell, Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major (37) Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. Saliba an, Harb ar, and Taher a, Front pharmacol Journal of Blood Medicine, vol.5, issue.2015, pp.2176-197, 2014.

C. Hsiu-hao, L. Meng-yao, S. Shinn-forng, Y. Peng, and . Yang, The long-term efficacy and tolerability of oral deferasirox for patients with transfusion dependent ?-thalassemia in Taiwan, Ann Hematol, issue.12, pp.941945-1952, 2015.

. K. 'enfant, D. Dick, O. Kouamé, L. Ouattara, I. Nigue et al., Hematopoietic stem cell transplantation for people with ßthalassaemia major (43) http://www.institutpaolicalmettes.fr/en/cancer-et-soins/les-cancers-prisen- charge-a-lipc/hematology/comprendre-la-compatibilite-hla/ (44) French Multicenter 22-Year Experience in Stem Cell Transplantation for Beta-Thalassemia Major: Lessons and Future Directions. for the French Rare Disease Center for Thalassemia and the French Society of Bone Marrow Transplantation, Intérêts des splénectomies au cours des drépanocytoses et thalassémies majeures de l Journal de pédiatrie et de puériculture 2005, pp.333-339, 2013.

. Cavazzanna, Essai clinique : « Une étude ouverte de Phase 1/2 évaluant la sécurité et l'efficacité de la thérapie génique des ?hémoglobinopathies (drépanocytose et ?-thalassémie majeure) par transplantation de cellules souches CD34+ autologues transduites ex vivo avec un vecteur lentiviral ?A-T87Q globine (LentiGlobin® BB305 Drug Product) ». ANSM. 3 Mai 2012 http://ansm.sante.fr/var/ansm_site/storage/original/application/989b21e50ad45d aa4445c2c52cff849b.pdf (50) Outcomes of Gene Therapy for Severe Sickle Disease and Beta- Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis, Fiche d'information destinée au public pour les essais cliniques portant sur des organismes génétiquement modifiés, pp.3829-3865, 2012.

S. Gardenghi, P. Ramos, M. Marongiu, L. Melchiori, L. Breda et al., Hepcidin as a therapeutic tool to limit iron overload and improve anemia in ??-thalassemic mice, Journal of Clinical Investigation, vol.120, issue.12, pp.4466-77, 2010.
DOI : 10.1172/JCI41717DS1

G. Preza, P. Ruchala, R. Pinon, E. Ramos, B. Qiao et al., Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload, Journal of Clinical Investigation, vol.121, issue.12, pp.4880-4888, 2011.
DOI : 10.1172/JCI57693DS1